Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis.
Otake H, Ako J, Yamasaki M, Tsujino I, Shimohama T, Hasegawa T, Sakurai R, Waseda K, Honda Y, Sood P, Sudhir K, Stone GW, Fitzgerald PJ. Otake H, et al. Among authors: shimohama t. Am J Cardiol. 2010 Aug 15;106(4):492-7. doi: 10.1016/j.amjcard.2010.03.059. Am J Cardiol. 2010. PMID: 20691306 Clinical Trial.
Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.
Otake H, Honda Y, Courtney BK, Shimohama T, Ako J, Waseda K, Macours N, Rogers C, Popma JJ, Abizaid A, Ormiston JA, Spaulding C, Cohen SA, Fitzgerald PJ. Otake H, et al. Among authors: shimohama t. Circ Cardiovasc Interv. 2011 Apr 1;4(2):146-54. doi: 10.1161/CIRCINTERVENTIONS.110.957175. Epub 2011 Mar 8. Circ Cardiovasc Interv. 2011. PMID: 21386089 Clinical Trial.
Intravascular ultrasound insights from the Cobalt Chromium Stent With Antiproliferative for Restenosis II (COSTAR II) trial comparing CoStar and Taxus paclitaxel-eluting stents.
Tsujino I, Koizumi T, Shimohama T, Ako J, Waseda K, Krucoff M, Honda Y, Fitzgerald PJ. Tsujino I, et al. Among authors: shimohama t. Cardiovasc Revasc Med. 2012 Mar-Apr;13(2):111-8. doi: 10.1016/j.carrev.2012.01.010. Epub 2012 Mar 8. Cardiovasc Revasc Med. 2012. PMID: 22406056 Clinical Trial.
Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial.
Yamasaki M, Tsujino I, Lima-Filho MO, Ako J, Shimohama T, Hasegawa T, Sakurai R, Sudhir K, Stone GW, Waseda K, Honda Y, Fitzgerald PJ. Yamasaki M, et al. Among authors: shimohama t. EuroIntervention. 2012 Oct;8(6):724-31. doi: 10.4244/EIJV8I6A112. EuroIntervention. 2012. PMID: 23086791 Free article. Clinical Trial.
The risks and benefits of drug-eluting stents.
Shimohama T, Honda Y, Fitzgerald PJ. Shimohama T, et al. Am Heart Hosp J. 2007 Summer;5(3):146-50. doi: 10.1111/j.1541-9215.2007.07379.x. Am Heart Hosp J. 2007. PMID: 17673855 No abstract available.
69 results